11 participants
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2022-09-15
- Start Date:
- 2020-07-17
- Completion:
- 2022-09-11
Conditions
- AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
Interventions
- DRUG
No Results Yet